Buscar
Congreso SOLACI
HomeAHA 2012.Day 2

Day 2

Ver Categoría
Day 2

PHS II Trial: Use of multivitamins in the prevention of cardiovascular disease in men.

Observational studies have shown contradicting results on the use of multivitamins. PHS II is the only randomized...
solaci -
Ver más
Day 2

GAUSS trial: Antibodies for the treatment of hypercholesterolemia in patients with statin intolerance.

Statins are the most effective treatment to reduce LDL levels and cardiovascular risk, 10-20% of patients are...
solaci -
Ver más
Day 2

DALCETRAPIB: Dalcetrabib for the treatment of ACS

High levels of HDL are known to exert a protective effect. In previous studies, dalcetrapib administration increased...
solaci -
Ver más
Day 2

Monoclonal antibodies for the treatment of dislipidemia in patients on maximal dose statins.

Statins are first-line therapy for hypercholesterolemia. However, many patients are not able to achieve their goals despite...
solaci -
Ver más
Day 2

FORWARD Trial: Use of Omega 3 to prevent recurring atrial fibrillation

Atrial fibrillation (AF) is a very prevalent arrhythmia and there is no known drug, device or ablation...
solaci -
Ver más
Day 2

OPERA Trial: Use of Omega 3 to prevent post-operative atrial fibrillation

Atrial fibrillation (AF) prolongues post-operative central vascular surgery, increasing morbidity and costs. Though smaller, a few trials...
solaci -
Ver más
Day 2

UMPIRE Trial: the polypill proves effective in treating high risk patients.

A polypill is an interesting strategy for cardiac patients requiring multiple drugs. This trial involved 2138 patients...
solaci -
Ver más

SOLACI es la organización de referencia del intervencionismo cardiovascular latinoamericano.

Últimas Noticias

EuroSMR Registry: Edge-to-Edge Mitral Treatment with 5-Year Outcomes

solaci - 0
Cardiomyopathies and left atrial enlargement can lead to secondary mitral regurgitation (SMR). This condition is associated with ventricular dysfunction, causing heart failure, hospitalization, and...

TricValve Transcatheter Bicaval Valve System for Severe Tricuspid Insufficiency: Events at One Year

Dr. Omar Tupayachi - 0
TricValve is the first bicaval valve system to obtain CE-Mark approval. This device heterotopic device eliminates tricuspid insufficiency reflux into the venous system, reducing...

Long Term Results of the International Chimney Registry

Dr. Omar Tupayachi - 0
The International Chimney Registry was an observational study aimed at assessing the use of chimney stenting during TAVR either to predict or treat coronary...

Noticias Institucionales

Hemodynamics and Interventional Cardioangiology Hybrid Training Course SOLACI-CACI

solaci - 0
We are now open for registration to the hybrid training course on Hemodynamics and Interventional Cardioangiology for Technicians and Nurses SOLACI-CACI 2025 Find all course...

Check out the best images of the El Salvador 2024 Sessions

solaci - 0
Review the highlights of the XLIX SOLACI Regional Sessions held at the Intercontinental Hotel in San Salvador, El Salvador between November 7 and 8,...

The El Salvador 2024 Sessions are coming soon

solaci - 0
The XLIX SOLACI 2024 Regional Sessions (17th Central America & the Caribbean) are approaching, and will take place in the city of San Salvador (El Salvador)....

Accesos

Adolfo Alsina 2653 · Piso 2H · CABA · Buenos Aires · Argentina · (5411) 4954 7173 · info@solaci.org · solaci.org · Términos de uso -Políticas de privacidad